No­vo Nordisk sus­pend­ed from lead­ing UK trade group over obe­si­ty mar­ket­ing 'breach'

No­vo Nordisk was slapped with a two-year sus­pen­sion from the UK phar­ma in­dus­try group, the As­so­ci­a­tion of the British Phar­ma­ceu­ti­cal In­dus­try (ABPI), on Thurs­day for cross­ing the line on its code of con­duct.

The sus­pen­sion stems from an in­ves­ti­ga­tion by the Pre­scrip­tion Med­i­cines Code of Prac­tice Au­thor­i­ty (PM­C­PA), which over­sees the com­plaints pro­ce­dure of the ABPI Code, over a LinkedIn post pro­mot­ing a “free weight man­age­ment course” by a third-par­ty provider that was sup­port­ed by No­vo Nordisk.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.